SCHEMBL25836755

SCHEMBL25836755

CC(NC(=O)OC(C)(C)C)c1cn(CC(N)=O)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.38
TSHR P16473 3/20 0.37
HSD17B10 Q99714 3/20 0.37
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA7 P43166 2/20 0.36
ALDH1A1 P00352 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAPT P10636 1/20 0.35
ATM Q13315 1/20 0.35
TRPA1 O75762 1/20 0.35
CA4 P22748 1/20 0.34
CA9 Q16790 1/20 0.34
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.33
CYP2D6 P10635 1/20 0.33
FLT4 P35916 1/20 0.33
JAK2 O60674 1/20 0.33
MEN1 O00255 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25836737 0.89 CYP2D6 (0.39) KMT2ATSHRHSD17B10CA1CA2
SCHEMBL23357725 0.86 CTSS (0.37) KMT2AATMTRPA1MEN1
SCHEMBL28503393 0.85 CTSK (0.34) HSD17B10CA1CA2CA7ATM
SCHEMBL25836705 0.77 DGAT2 (0.44) KMT2ATSHRHSD17B10CA1CA2
SCHEMBL25836754 0.75 CA1 (0.44) CA1CA2CA7ALDH1A1L3MBTL1
SCHEMBL25394615 0.75 AAK1 (0.32) CA1CA2CA7ATMCA9
SCHEMBL23038453 0.75 CTSS (0.38) KMT2ACA1CA2CA7ALDH1A1
SCHEMBL30455998 0.74 CTSS (0.35) KMT2ACA1CA2CA7ALDH1A1
SCHEMBL23651564 0.67 KMT2A (0.43) KMT2ATSHRHSD17B10CA1CA2
SCHEMBL14841095 0.67 ATM (0.45) KMT2ATSHRHSD17B10L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230287009-A1 OXO-SUBSTITUTED COMPOUND Sumitomo Pharma Co., Ltd. (JP) 2023-09-14 US disclosed
US-11702431-B2 Oxo-substituted compound Sumitomo Pharma Co., Ltd. (JP) 2023-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702431-B2 Oxo-substituted compound CYP51A1, OXA1L, O60361 KMT2A 2610/4885TSHR 4401/4885HSD17B10 306/4885
US-20230287009-A1 OXO-SUBSTITUTED COMPOUND CYP51A1, OXA1L, O60361 KMT2A 2610/4885TSHR 4401/4885HSD17B10 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.